Lotus Pharmaceutical

CompanyTaiwan

Lotus Pharmaceutical develops 2 assets, the furthest approved (metformin in type 2 diabetes). Mostly small molecule acting on AMPK signalling, glycolysis and Mitochondrial biogenesis (PGC-1α); based in Taiwan.

Assets
2
Furthest
Approved
Trials
1
Signals
0

Pipeline

2

  • metformin

    Activates AMPK and reduces hepatic gluconeogenesis

    ApprovedSmall moleculeMitochondrial biogenesis (PGC-1α)AMPK signallingtype 2 diabetesaging (Phase 3)

  • Acarmet

    Combination of metformin and acarbose to improve glycemic control by reducing glucose production and intestinal carbohydrate absorption.

    Phase 3Small moleculeAMPK signallingGlycolysisplus acarbose 50 mg tablets thrice daily versus acarbose 50 mg thrice daily over 16 week insubject with type 2 diabetes mellitus

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms8
  • Trials1
  • Signals5
  • Similar companies6

Updated 7 Oct 2026 · 51 sources

Intelligence